All Type of News
Pharmacy circles’ difficulties in acquiring ‘Tamiflu’ over flu outbreak
In regards to the recent outbreaks of influenza virus(flu), the pharmacy circles are busy supplying ‘Tamiflu.’ Although the number of patients visiting hospitals and clinics for flu, the number of treatments is still ...
MSD Korea’s margin cut fueled ‘Campaign to Revive Korean Drugs’The MSD Korea’s policy to reduce distribution margins has fueled the pharmaceutical distribution industry’s campaign to revive Korean drugs.
According to the distribution indus...
|
Daewoong Pharmaceutical’s open collaboration with Shenyang University
Daewoong Pharmaceutical(CEO Jong-Wook Lee) signed a memorandum of understanding(MOU) to cooperate with Shenyang University College of Pharmacy for joint research and development in various fields, such as new drug dev...
KDRA & KIRAMS sign ‘New Drug Development Agreement’
The Korea Drug Research Association(Chairman Dong-Yeon Kim, KDRA) and the Korea Institute of Radiological & Medical Sciences’(KIRAMS) Advanced Concept Medical Technology Development Platform Building Project Team(Team...
KPDA’s painstaking concerns over MSD’s margin cuts
The Korea Pharmaceutical Distribution Association(KPDA) is painstakingly seeking for measures to resolve the issue about MSD Korea’s distribution margin cuts.
The problem is even if MSD reduces their distribution mar...
MOHW’s personnel cut… total 23 civil servants from the ministry and its agencies
While the government has recently reduced the number of personnel, the Ministry of Health and Welfare(MOHW) is also planning to cut the number as well.
The MOHW announced a plan to cut the number of personnel working...
Yuhan recovers license for its non-small cell lung cancer therapy from Luoxin
Yuhan Corporation cancelled the technology export agreement of a targeted therapy for non-small cell lung cancer, YH25448, with a Chinese pharmaceutical company Luoxin Biotechnology.
According to Yuhan Coporation, th...
Chong Kun Dang and MSD Korea’s sales partnership for allergic rhinitis treatment
On the 26th, Chong Kun Dang(CEO Young-Joo Kim) announced a co-marketing agreement of ‘Nasonex,’ a allergic rhinitis treatment, with MSD Korea.
The agreement will allow Chong Kun Dang to exclusively sell and market N...
‘Pomalyst’ applied for insurance benefit while 48 products removed
From January next year, ‘Pomalyst Cap,’ a multiple myeloma treatment, will be applied for the health insurance benefit under the risk sharing(return type) application, and ‘Sunpla,’ a Korean new drug, will be removed ...
Competition to attract pharma distribution companies in online drug market
Online drug shopping malls operated by affiliates of pharmaceutical company are trying hard to make partnership with pharmaceutical distribution companies.
According to the industry concerned, it was told online drug...
